Benefits and potential harms of COVID-19 vaccination during pregnancy: evidence summary for patient counseling

E. Kalafat 1, P. O’Brien 2,3, P. T. Heath 4, K. Le Doare 4, P. von Dadelszen 5, L. Magee 5, S. Ladhani 6,7, A. Khalil 6,9

1 Koc University, School of Medicine, Department of Obstetrics and Gynaecology, Istanbul, Turkey
2 University College London Hospitals NHS Foundation Trust, London, UK
3 The Royal College of Obstetricians and Gynaecologists, London, UK
4 Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, St George’s University of London, London, UK.
5 Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK
6 Immunisation and Countermeasures Division, Public Health England
7 British Paediatric Surveillance Unit, Royal College of Pediatrics and Child Health
8 Fetal Medicine Unit, St George’s Hospital, St George’s University of London, UK
9 Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George’s University of London, UK

Corresponding author:
Professor Asma Khalil MRCOG MD MSc(Epi) DFSRH Dip (GUM)

Address:
Fetal Medicine Unit
Department of Obstetrics and Gynaecology
St. George’s University Hospitals NHS Foundation Trust
Blackshaw Road
London SW17 0QT
United Kingdom.
Email address: akhalil@sgul.ac.uk
Historically, pregnant women have been excluded from the majority of drug and vaccine trials, a practice that has been widely criticized by the scientific community. The result is that pregnant women are routinely denied beneficial, sometimes potentially life-saving, therapeutic and preventive measures, or receive them well after their non-pregnant peers. Data about safety and efficacy in pregnancy subsequently accumulate adventitiously as women receive the drug or vaccine not realising that they were pregnant, or fall pregnant soon after receiving the therapy. In the absence of any significant adverse effects, eventually sufficient confidence is established (either as 'evidence of no harm,' or, more frequently, as 'no evidence of harm') for a formal trial to be considered or alternatively, the use of the intervention in pregnancy simply slips into routine practice.

This pattern has been repeated with COVID-19 vaccines; pregnant women were excluded from the initial trials. Only a small number of women who were unknowingly pregnant or fell pregnant soon after vaccination have been included – this small cohort is currently being followed up as part of the original trials. Due to lack of evidence around the safety of these vaccines in pregnancy, international societies have tended to take a cautious approach, recommending that vaccination of pregnant women should be evaluated on a case-by-case basis. The Society of Obstetricians and Gynaecologists of Canada and the International Federation of Gynecology and Obstetrics are notable exceptions as early endorsers of unrestricted vaccination in pregnancy. In the United Kingdom (UK), the Royal College of Obstetricians and Gynaecologists (RCOG) suggests that pregnant women at very high risk should be considered eligible for vaccination; these criteria are under constant review and were recently updated on 24th of February. Proposed risk factors are derived from literature relating specifically to pregnant women with COVID-19 and also extrapolated from non-pregnant women with COVID-19. They consist primarily of chronic diseases or immunosuppressive conditions, as well as women at high risk of exposure to the virus (Table 1). It must also be acknowledged that women can experience severe COVID-19 even in the absence of any of these risk factors. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists have taken a stance similar to the RCOG. The American College of Obstetricians and Gynecologists (ACOG) recommends that ‘COVID-19 vaccines should not be withheld from pregnant women who meet criteria for vaccination based on ACIP (Advisory Committee on Immunization Practices) recommended priority groups’. Here we summarize the available evidence to support counseling for women contemplating COVID-19 vaccination during pregnancy.
Most pregnant women with COVID-19 will remain asymptomatic or have a mild illness. Fortunately, severe disease and death are rare outcomes. In the UK, for example, the maternal mortality rate associated with COVID-19 is 2.2 per 100,000 maternities. Pregnant women hospitalised with COVID-19, however, are more likely to be admitted to the Intensive Care Unit (ICU) compared to non-pregnant women with the infection, although it is unclear whether this represents more serious illness or a lower threshold for ICU admission. Despite this, according to a large systematic review, pregnant women do not appear to be at greater risk of death. Some studies from both high and low incomes settings, however, report increased maternal mortality. Summary findings should be contextualised if used during patient counseling. Compared with pregnant women without COVID-19, those with symptomatic COVID are at increased risk of adverse pregnancy outcomes, including maternal ICU admission, iatrogenic preterm birth, preeclampsia like symptoms, Caesarean section and death. Reports of stillbirth in the literature are very heterogeneous; rates seem to be increased in low to middle-income countries while there was no significant increase in high-income countries. COVID-19 has other indirect effects on maternal and fetal outcomes, such as increased maternal mental distress and intimate partner violence.

The risk of severe adverse outcomes (e.g., ICU admission, maternal death, or stillbirth) will be modified by individual and societal risk factors, and the availability and performance of healthcare in their setting. Nevertheless, it seems reasonable to counsel pregnant women with obesity, advanced age, or significant chronic conditions (Table 1) that they are at increased risk of severe COVID-19 and, therefore, more likely to benefit from vaccination in terms of protection from life-threatening COVID-19 (Table 2). Observational studies indicate that postnatal transmission of SARS-CoV-2 from mother to baby is rare, and continued breastfeeding appears to be safe. The minimal postnatal transmission risk will probably be even lower in vaccinated mothers. The presence of anti-SARS-CoV-2 IgG has been reported in the neonate of a vaccinated mother, but it is not yet possible to say what impact maternal vaccination will have on neonatal protection against infection after birth. Other secondary adverse effects of COVID-19 include mother-infant separation in some settings, increased Caesarean section and iatrogenic preterm birth. The incidence of these adverse effects is likely to be reduced by vaccination too and women should be counselled about the probable additional benefits of vaccination over and above protection from severe disease (Table 2).
Available vaccines and their safety profiles

Four different types of COVID-19 vaccine are currently available: mRNA, viral vector, inactivated virus, and recombinant antigen (Table 3). As yet, only three COVID-19 vaccines, two mRNA and one adenoviral vector, are approved for emergency use by both the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), namely mRNA-1273 (Moderna Therapeutics, Cambridge, MA, USA), BNT162b2 (BioNTech, Fosun Pharma, Pfizer, Mainz, Germany) and Ad.26.COV2 (Janssen Pharmaceutica, Beerse, Belgium). The Oxford-AstraZeneca (AZD1222), another viral vector vaccine approved by the EMA, is commonly used in the UK. The two FDA approved mRNA vaccines were shown to elicit a very strong immune response and protection against severe COVID-19\textsuperscript{4,26}. Unpublished mRNA vaccine (mRNA-1273) data from a study of pregnant rats identified no safety concerns regarding malformations or embryotoxicity\textsuperscript{27}. Trials of both vaccines excluded pregnant women. Initial reports from regulatory bodies, such as the EMA, show that a small number of women in the trial were pregnant at the time of vaccination; safety data from these pregnancies are still pending but, as yet, no significant adverse effects have been observed\textsuperscript{28,29}. More recently, Dr Anthony Fauci, Chief Medical Advisor to US President Biden, stated that more than 20,000 pregnant women have received an mRNA vaccine and to date there have been no concerning ‘red flags’\textsuperscript{30,31}. These as yet unpublished data illustrate that many pregnant women are willing to be vaccinated when their autonomy is respected and they have the opportunity to weigh their own personal risks and benefits. These preliminary safety data are reassuring and their publication is eagerly awaited.

Although mRNA vaccines have never previously been deployed on such a scale, they are not new. mRNA vaccines are not live virus vaccines and do not use an adjuvant to increase vaccine efficacy. The mRNA does not enter the cell nucleus and cannot alter the human genome in vaccinees. Animal studies have demonstrated the safety, efficacy, and potential benefit of mRNA vaccines in pregnant women, benefits which may extend beyond simply protecting the mother from pathogens. Zika virus is a zoonotic pathogen, like coronavirus, and is capable of intrauterine infection. In 2018, Richner et al. published a report describing the efficacy of an mRNA vaccine against Zika virus in pregnant mice\textsuperscript{32}. Following vaccination, pregnant mice were infected with live Zika virus; pups born to vaccinated dams showed no viral load in their brain tissue. Furthermore, the viral load was at or below the detection threshold in placental samples. The authors concluded that the mRNA vaccine was safe in pregnant mice and that it prevented vertical transmission of Zika virus. The principles of this vaccination technology should also apply to COVID-19 vaccines, and
provides generic reassurance around the use of mRNA vaccines in pregnancy. Furthermore, vaccination is likely to protect not only the pregnant woman but also the fetus and neonate. With regards to COVID-19 vaccines, for example, a recent case report demonstrated transplacental transmission of antibodies against the spike protein following vaccination of the mother\textsuperscript{24,25}. Efficient transplacental transfer of SARS-CoV-2 IgG antibodies in the majority of seropositive pregnant women after natural infection has also been shown\textsuperscript{33}. The presence of neutralizing antibodies in the fetal/neonatal circulation is potentially an added benefit of vaccination for protection of the baby, in both fetal and neonatal life, against COVID-19.

Three adenoviral vaccines Oxford-AstraZeneca AZD1222, Janssen Ad.26.COV2 and Gam-COVID-Vac, (also known as Sputnik V) have recently reported Phase 3 trial data showing high levels of efficacy against COVID-19, especially against severe disease and hospitalization\textsuperscript{5,34,35}. As with the mRNA vaccines there are limited data on the safety of adenovirus vector vaccines in pregnancy, though adenovirus vector-based Zika vaccines have been tested in pregnant mice without safety concerns\textsuperscript{36}. These vaccines do not contain live virus and neither the COVID protein nor the adenovirus vector replicates in humans, and are eliminated from the tissues following injection.

Two inactivated virus vaccines from China (BBIBP-CorV, Beijing Institute of Biological Products, China; CoronaVac, Sinovac Life Sciences, Beijing, China) and one from India (Bharat Biotech) are commercially available. Varying efficacy rates for preventing symptomatic infection have been reported\textsuperscript{37-41}. However, they had similarly high protection against severe COVID-19 and death. Inactivated virus vaccines are considered safe in pregnancy, though the aluminium oxide adjuvant used in these vaccines do not have a designated FDA safety category due to the lack of data\textsuperscript{42,43}. However, alum adjuvants are used in many vaccines, including Hepatitis B, DTaP and human papillomavirus (HPV). Inadvertent vaccination with HPV vaccines during pregnancy has not been associated with any safety concerns\textsuperscript{44}. A similar safety profile was observed with respiratory syncytial virus vaccine, which also uses alum adjuvant\textsuperscript{45}.

There is one recombinant antigen vaccine (Novavax) that showed high efficacy against symptomatic SARS-CoV-2 infection\textsuperscript{46}. The antigens produced by recombinant technology are coupled with a saponin-based proprietary adjuvant in order to elicit an immune response. Recombinant vaccines are considered safe in pregnancy due to their non-replicating nature. However, the saponin-based proprietary adjuvant used in this vaccine lacks safety data in pregnant women.
Ongoing trials and pending safety data

Pregnancy trials of BNT162b2 (BioNTech, Fosun Pharma, Pfizer) and Ad.26.COV2 (Janssen Pharmaceutica) are due to start soon. However, enrolment to prospective trials is threatened by the current global demand for vaccines, which will only increase with time. Worldwide, pregnant women are already choosing to be vaccinated against COVID-19, and safety data accumulating in official registries are likely to play a key role for expectant mothers considering vaccination. It is essential that countries establish national registries of pregnant women receiving the different types of COVID-19 vaccine as a matter of urgency; where possible, international registries should be developed. Monitoring pregnancy, foetal and neonatal outcomes in vaccinated women and comparing them with those in unvaccinated pregnant women must be a priority.

Moreover, the ethics of enrolling pregnant women into placebo controlled trials is increasingly questionable, at a time when more and more pregnant women, particularly those with risk factors for severe COVID-19, are already receiving the vaccine. These vaccines are likely to deliver similar benefit to pregnant women as to non-pregnant individuals, and are likely to be safe. Withholding such a vaccine from prospective mothers who understand and accept the uncertainty of available preventive measures, while offering them enrolment into a placebo-controlled trial, might prove ethically challenging. Nevertheless, there are a number of advantages in recruiting pregnant women into trials in which they receive a licensed COVID-19 vaccine. This includes addressing questions around optimal timing of vaccinations, number of doses, dose intervals and need for boosters in future pregnancies. In the meantime, animal studies should be rapidly undertaken to provide safety information about the current unknowns of COVID-19 vaccines, such as transplacental passage of mRNA containing lipids or the safety of adjuvants and adenoviral vectors. There is an urgent need to focus and allocate more resources to research COVID-19 vaccination in pregnancy while awaiting safety data from official registries.

Conclusions

Pregnant women should be provided with a balanced and clear assessment of their risk of COVID-19 in pregnancy, taking into account their individual circumstances, local practices and available evidence from similar healthcare settings. In addition, they should be counselled with a balanced summary of the potential direct and indirect benefits of COVID-
19 vaccines, while acknowledging the limited safety data. Whilst these vaccines have not yet been trialled in pregnancy, they are being offered to pregnant women with risk factors for severe COVID-19 during the national rollout of vaccine programmes in the UK. These vaccines are also currently offered to pregnant women with a high risk of exposure to SARS-CoV-2, including health and care workers. In the UK, the MHRA is receiving regular feedback from the vaccination programme and any concerns are met with appropriate action. So far, no safety concerns in vaccinated pregnant women have been reported in either the UK or the US. We believe that COVID-19 vaccination should not be withheld from pregnant women who have received adequate counselling and understand the uncertainties, minimal potential harms, and likely benefits of these vaccines. We also encourage further research to address current and future issues around COVID vaccines in pregnancy.
REFERENCES

1. Heath PT, Le Doare K, Khalil A. Inclusion of pregnant women in COVID-19 vaccine development. Lancet Infect Dis. 2020;20(9):1007-8.

2. Taylor MM, Kobeissi L, Kim C, Amin A, Thorson AE, Bellare NB, et al. Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. The Lancet Global Health.

3. Dashraath P, Nielsen-Saines K, Madhi SA, Baud D. COVID-19 vaccines and neglected pregnancy. Lancet. 2020;396(10252):e22. doi:10.1016/S0140-6736(20)31822-5

4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Curtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. NEJM. 2020;383(27):2603-15.

5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.

6. Society of Obstetricians and Gynaecologists of Canada. SOGC Statement on COVID-19 Vaccination in Pregnancy. https://sogc.org/common/Uploaded%20files/Latest%20News/SOGC_Statement_COVID-19_Vaccination_in_Pregnancy.pdf. Published 2021. Accessed March 13, 2021.

7. FIGO (International Federation Fegynecology and Obstetrics). COVID-19 Vaccination for Pregnant and Breastfeeding Women. Figo.org. https://www.figo.org/sites/default/files/2021-03/FIGO%20Statement_COVID-19%20vaccination%20pregnant%20breastfeeding%20women_EN.pdf. Published 2021. Accessed March 13, 2021.

8. Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding. Royal College of Obstetricians & Gynaecologists. https://www.rcog.org.uk/en/news/updated-advice-on-covid-19-vaccination-in-pregnancy-and-women-who-are-breastfeeding/. Published 2021. Accessed February 14, 2021.

9. Royal college of obstetricians and gynaecologists. Merged information sheet and decision aid. Rcg.org.uk. https://www.rcog.org.uk/globalassets/documents/guidelines/2021-02-24-combined-info-sheet-and-decision-aid.pdf. Published 2021. Accessed March 13, 2021.

10. Vaccinating Pregnant and Lactating Patients Against COVID-19. Acog.org. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19. Published 2021. Accessed February 14, 2021.

11. Barrantes JH, Ortoleva J, O'Neil ER, Suarez EE, Beth Larson S, Rali AS, et al. Successful Treatment of Pregnant and Postpartum Women With Severe COVID-19 Associated Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. ASAIO Journal. 2021;67(2).

12. RANZCOG - COVID-19 Vaccination Information. Ranzcog.edu.au. https://ranzcog.edu.au/statements-guidelines/covid-19-statement/covid-19-vaccination-information. Published 2021. Accessed March 13, 2021.

13. Khalil A, Kalafat E, Benlioglu C, O'Brien P, Morris E, Draycott T, et al. SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020;25:100446.

14. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320.

15. Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Mortal Mortal Wkly Rep. 2020;69(44):1641-1647. Published 2020 Nov 6. doi:10.15585/mmwr.mm6944e3

16. Jering KS, Claggett BL, Cunningham JW, Rosenthal N, Vardeny O, Greene MF, et al. Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19. JAMA Internal Medicine. 2021.

17. Martinez-Portilla RJ, Sotiriadis A, Chatzakazis C, Torres-Torres J, Espino y Sosa S, Sandoval-Mandujano K, et al. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol. 2021;57(2):224-31.
18. Khalil A, von Dadelszen P, Draycott T, Ugwumadu A, O'Brien P, Magee L. Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic. JAMA. 2020;324(7):705-6.

19. Chmielewska B, Barratt I, Townsend R, Kalafat E, van der Meulen J, et al. Impact of the COVID-19 pandemic on maternal and perinatal outcomes: A systematic review and meta-analysis. Lancet Glob Health. 2021 [epub ahead of print]

20. Evans ML, Lindauer M, Farrell ME. A Pandemic within a Pandemic — Intimate Partner Violence during Covid-19. NEJM. 2020;383(24):2302-4.

21. Walker KF, O'Donoghue K, Grace N, Dorling J, Comeau JL, Li W, et al. Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. Bmjog. 2020;127(11):1324-36.

22. Salvatore CM, Han JY, Acker KP, Tiwari P, Jin J, Brandler M, et al. Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study. The Lancet Child & adolescent health. 2020;4(10):721-7.

23. Centeno-Tablante E, Medina-Rivera M, Finkelstein JL, et al. Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review. Ann N Y Acad Sci. 2021;1484(1):32-54. doi:10.1111/nyas.14477

24. Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al. Transplacental Transfer of SARS-CoV-2 Antibodies. medRxiv. 2020:2020.10.07.20207480.

25. Gill L, Jones CW. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy. Obstetrics & Gynecology. 9900;Latest Articles.

26. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. NEJM. 2020;384(5):403-16.

27. FDA Briefing Document Moderna COVID-19 Vaccine. Fda.gov. https://www.fda.gov/media/144434/download. Published 2021. Accessed February 14, 2021.

28. Comirnaty: EPAR - Public assessment report. Ema.europa.eu. https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf. Published 2021. Accessed February 14, 2021.

29. Male V. Are COVID-19 vaccines safe in pregnancy? Nature Reviews Immunology. 2021.

30. Press Briefing by White House COVID-19 Response Team and Public Health Officials | The White House. The White House. https://www.whitehouse.gov/briefing-room/press-briefings/2021/02/10/press-briefing-by-white-house-covid-19-response-team-and-public-health-officials-3/. Published 2021. Accessed March 12, 2021.

31. Advisory Committee on Immunization Practices (ACIP). COVID-19 vaccine safety update. Cdc.gov. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/28-03-01/05-covid-Shimabukuro.pdf. Published 2021. Accessed March 12, 2021.

32. Logunov DY, Dolzhikova IV, Shchelyakov DV, Tukhvatulin Al, Zubkova OV, Dzhurullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021

33. Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use | Johnson & Johnson. Content Lab U.S. https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-use-first-single-shot-vaccine-in-fight-against-global-pandemic. Published 2021. Accessed March 12, 2021.

34. Larocca RA, Mendes EA, Abbink P, Peterson RL, Martinot AJ, Iampietro MJ, et al. Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− Mice. Cell Host & Microbe. 2019;26(5):591-600.e4.

35. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51.
38. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92.

39. Vaccines against COVID-19 in the UAE - The Official Portal of the UAE Government. U.ae. https://u.ae/en/information-and-services/justice-safety-and-the-law/handling-the-covid-19-outbreak/vaccines-against-covid-19-in-the-uae. Published 2021. Accessed February 14, 2021.

40. Turkish study revises down Sinovac COVID-19 vaccine efficacy to 83.5%. U.S. https://www.reuters.com/article/health-coronavirus-turkey-sinovac-int-idUSKBN2AV18P. Published 2021. Accessed March 14, 2021.

41. Bharat Biotech Announces Phase 3 Results of COVAXIN®: India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%. Bharatbiotech.com. https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf. Published 2021. Accessed March 14, 2021.

42. Batista-Duharte A, Martínez DT, Carlos IZ. Efficacy and safety of immunological adjuvants. Where is the cut-off? Biomedicine & Pharmacotherapy. 2018;105:616-24.

43. Herberts C, Melgert B, van der Laan JW, Faas M. New adjuvanted vaccines in pregnancy: what is known about their safety?. Expert Rev Vaccines. 2010;9(12):1411-1422. doi:10.1586/erv.10.133

44. Scheller NM, Pasternak B, Melgaard-Nielsen D, Svanström H, Hvid A. Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes. NEJM. 2017;376(13):1223-33.

45. Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, et al. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. NEJM. 2020;383(5):426-39.

46. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial | Novavax Inc. - IR Site. Novavax Inc. - IR Site. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3. Published 2021. Accessed February 14, 2021.

47. Public Health England. Inadvertent vaccination in pregnancy (VIP). GOV.UK. https://www.gov.uk/guidance/vaccination-in-pregnancy-vip. Published 2021. Accessed March 13, 2021.

48. UKOSS. COVID-19 Vaccination in Pregnancy | UKOSS. Npeu.ox.ac.uk. https://www.npeu.ox.ac.uk/ukoss/current-surveillance/covid-19-vaccination-in-pregnancy. Published 2021. Accessed March 13, 2021.
Table 1. Risk groups for pregnant women, for whom vaccination should be considered according to the Royal College of Obstetricians and Gynaecologists (RCOG).

| **Risk factors for serious COVID-19** |  |
|-------------------------------------|--|
| • Underlying medical conditions such as immune conditions, diabetes, high blood pressure, heart disease or asthma |  |
| • Overweight |  |
| • Age over 35 |  |
| • Third trimester pregnancy (over 28 weeks) |  |

| **Risk factors for catching COVID-19** |  |
|---------------------------------------|--|
| • Health or social care worker in the same household |  |
| • Increased rate of COVID-19 infections in the woman’s community |  |
| • Frequent contact with people outside the home |  |
| • Not being able to comply with social distancing |  |
| • Crowded household |  |
| • Black, Asian or minority ethnicity background |  |
Table 2. Direct and indirect detrimental effects of COVID-19 on pregnant women and the potential effect of vaccination

| Adverse effects                        | Incidence | Mediator                                      | Potential effect of vaccination |
|----------------------------------------|-----------|-----------------------------------------------|---------------------------------|
| Maternal ICU admission                 | Rare      | COVID-19, direct                              | Prevention                      |
| Mechanical ventilation or ECMO         | Rare      | COVID-19, direct                              | Prevention                      |
| Maternal death                         | Rare      | COVID-19, direct                              | Prevention                      |
| Iatrogenic preterm birth               | Common    | COVID-19, indirect                            | Reduction                       |
| Caesarean section                      | Common    | COVID-19, indirect                            | Reduction                       |
| Stillbirth                              | Rare      | Severe COVID-19, reduced healthcare access   | Reduction                       |
| Increased mental distress scores       | Common    | Reduced healthcare access, pandemic or mitigation measures | Unknown                       |
| Mother-infant separation following delivery | Uncommon | Perceived risk of transmission                | Reduction                       |
| Interruption of breastfeeding following delivery | Uncommon | Perceived risk of transmission or COVID-19 treatment incompatible with nursing | Reduction                       |
| Vertical transmission                   | Rare      | COVID-19, direct                              | Reduction/Prevention            |

ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation
Table 3. Available vaccines with available phase III trial results. All listed vaccines have very high protection rates against serious and life-threatening COVID-19 infection.

| Vaccine          | Technology | Property     | Direct safety data                                                                 | Indirect safety data from vaccines using similar technology                                                                 | Unknowns and theoretical safety concerns                                                                 |
|------------------|------------|--------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| mRNA-1273        | mRNA       | Non-replicating | Tested on pregnant mice: no signs of embryonal, fetal or postnatal developmental problems | mRNA based ZIKA virus vaccine used in pregnant mice                                                                             | Transplacental passage of mRNA containing lipids                                                                 |
| BNT162b2         | mRNA       | Non-replicating | NA                                                                                 |                                                                                                                              |                                                                                                           |
| AZD1222          | Viral vector | Non-replicating | NA                                                                                 | Adenovirus based ZIKA virus vaccine used in pregnant mice                                                                    |                                                                                                           |
| Ad.26.COV2       | Viral vector | Non-replicating | NA                                                                                 |                                                                                                                              |                                                                                                           |
| Gam-COVID-Vac    | Viral vector | Non-replicating | NA                                                                                 |                                                                                                                              |                                                                                                           |
| BBIBP-CorV       | Inactivated virus with aluminium hydroxide adjuvant | Non-replicating | NA                                                                                 | Inactivated vaccines are considered safe during pregnancy. Alum adjuvant has been used in vaccines that are considered safe during pregnancy (HPV, RSV) | Alum adjuvant                                                                                             |
| CoronaVac        | Inactivated virus with aluminium hydroxide adjuvant | Non-replicating | NA                                                                                 |                                                                                                                              | Alum adjuvant                                                                                             |
| Novavax          | Recombinant antigen with saponin based adjuvant      | Non-replicating | NA                                                                                 | Recombinant vaccines are considered safe during pregnancy. Saponin based proprietary adjuvant                                |                                                                                                           |